Business / Finance

RSS

IDT opens molecular biology R&D facility in Redwood City

Already the world’s leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.

From Integrated DNA Technologies 28 Apr 2015

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").

28 Apr 2015

Main Street fully exits investment in California Healthcare Medical Billing

Main Street Capital Corporation announced that it recently fully exited its investment in California Healthcare Medical Billing, Inc. CHMB is a provider of outsourced medical billing, revenue cycle management, practice management and electronic health record (EHR) solutions to physicians, clinics, hospitals and health systems throughout the United States.

28 Apr 2015

NeoGenomics' revenue increases 27% to $23.0 million in first quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015.

28 Apr 2015

PAML signs collaborative agreement with Axela

PAML announced today that the laboratory has entered into a collaborative agreement with Axela, Inc. to develop multiplex assays focused on immune status for vaccine preventable diseases. PAML is one of the nation's leading medical reference laboratories, and Axela focuses on multiplexed nucleic acid and protein analysis for clinical diagnostics.

28 Apr 2015

Universal Health Services announces net income of $174.3 million for first quarter 2015

Universal Health Services, Inc. announced today that its reported net income attributable to UHS was $174.3 million, or $1.73 per diluted share, during the first quarter of 2015 as compared to $138.1 million, or $1.38 per diluted share, during the comparable quarter of 2014.

28 Apr 2015

MiMedx Group's revenue increases 108% to $40.8 million in first quarter 2015

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the first quarter of 2015.

28 Apr 2015

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.

28 Apr 2015

Boston Scientific, Brainlab form strategic collaboration

Boston Scientific Corporation announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical navigation.

28 Apr 2015

MicroCare Medical Highlights its most Advanced Products at Med-Tech Innovations

One of the newest product updates to be exhibited is MicroCare Duraglide® dry lubricant. Offering unparalleled lubricity, the fast-drying Duraglide® fluids leave a smooth, even, slippery coating on any surface...

27 Apr 2015

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories").

27 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

American Securities signs agreement to acquire Royal Adhesives and Sealants

American Securities LLC and Arsenal Capital Partners today announced that American Securities has partnered with management and signed a definitive agreement to acquire Royal Adhesives and Sealants, LLC, a leading producer of proprietary, high-performance adhesives and sealants, from Arsenal Capital Partners.

27 Apr 2015

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share.

27 Apr 2015

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.

27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology.

From Natera 25 Apr 2015

Lannett amends, increases revolving credit facility from $50 million to $120 million

Lannett Company, Inc. today announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an accordion feature that will allow the company to increase borrowings by a total of up to an additional $30.0 million, subject to securing additional commitments from existing lenders or new lending institutions.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service (DATIS) based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015